The Zhitong Finance App learned that RegenLab USA, a medical device company focusing on regenerative medicine such as tissue repair, announced the IPO terms on Tuesday. The Jersey City, New Jersey-based company plans to raise $18 million by issuing 2.5 million shares at a price of 6 to 8 dollars each. Based on the median of the proposed issue price range, RegenLab USA will reach a market capitalization of US$157 million after complete dilution.
RegenLab develops and produces disposable devices that can prepare autologous platelet-rich plasma (PRP) at diagnosis and treatment sites, and can be used alone or in combination with hyaluronic acid (HA). Its products are used in musculoskeletal, wound care, medical aesthetics, and women's health. The company's two main products are RegenKit, a PRP preparation kit, and Cellular Matrix, a PRP-HA composite product for knee osteoarthritis. Most products have obtained European CE certification; several Regenkit products, including a Medicare-covered wound gel, have been approved by the US FDA. Cellular Matrix has not been approved in the US and is currently in the PMA (Pre-Market Approval) process. The company was founded in 2003 in Switzerland, has production facilities in Switzerland, France and New Jersey, and sells in around 90 countries through direct sales teams and distributors.
RegenLab USA was founded in 2003 and achieved revenue of US$54 million in the 12 months ending June 30, 2026. The company plans to list on NASDAQ under the ticker symbol “RGNA.” StoneX Financial acted as sole underwriter for this release.